Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

VentriPoint Diagnostics Ltd. (V:VPT)

Business Focus: Advanced Medical Equipment & Technology

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for VPT within the last 6 months
See all filings within the past 6 months

Company News

Oct 21, 2021 06:10 ET
Ventripoint Installs VMS+ 3.0 Unit at East Midlands Congenital Heart Centre
Toronto, Ontario – The Newswire – October 21, 2021 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that the East Midlands Congenital Heart Centre in Leicester, UK has received the VMS+3.0 unit.
Read full article
Oct 20, 2021 07:10 ET
Ventripoint Diagnostics Ltd. Announces Closing of Upsized Bought Deal Offering of Units
Toronto, Canada – TheNewswire - October 20, 2021 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT), (OTC:VPTDF), is pleased to announce that has closed its previously announced upsized bought-deal public offering (the “Offering”) including full exercise of the over-allotment option.
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Oct 15, 20211,456,142397,518
Sep 30, 20211,058,624258,073
Sep 15, 2021800,551762,580
See Short Report

Business Summary

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of cardiac diagnostic tools that monitor patients with heart disease. It offers Ventripoint Medical System (VMS) equipment. Its VMS+ is a diagnostic aid which is developed to provide a point of care solution to communicate the heart's structure and function without the need for magnetic resonance imaging (MRI). Its VMS+ is designed to create a three-dimensional (3D) model of heart from a two-dimensional (2D) echocardiogram and allows to obtain real time clinical data within minutes. Its Knowledge Based Reconstruction (KBR) algorithm leverages an MRI shape catalogue and anatomical landmarks from 2D echocardiogram images to construct a 3D model of the heart. Its KBR enables to construct a 3D model of the heart and calculates volumes and ejection fractions for all chambers.

See business summary



Search (past week) for $VPT.CA VPT.V